ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Author:

Zinzani Pier Luigi1ORCID,Mayer Jiří2ORCID,Flowers Christopher R.3ORCID,Bijou Fontanet4ORCID,De Oliveira Ana C.5ORCID,Song Yuqin6,Zhang Qingyuan7ORCID,Merli Michele8ORCID,Bouabdallah Krimo9,Ganly Peter10,Zhang Huilai11,Johnson Roderick12,Martín García-Sancho Alejandro13ORCID,Provencio Pulla Mariano14ORCID,Trněný Marek15ORCID,Yuen Sam16,Tilly Herve17ORCID,Kingsley Edwin18,Tumyan Gayane19,Assouline Sarit E.20ORCID,Auer Rebecca21ORCID,Ivanova Elena22,Kim Pil23,Huang Sha24,Delarue Richard22,Trotman Judith25ORCID

Affiliation:

1. IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

2. Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic

3. Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

4. Institut Bergonié, Bordeaux, France

5. Institut Catala d'Oncologia (ICO) Hospital Duran I Reynals, Hospital, Barcelana, Spain

6. Peking University Cancer Hospital and Institute, Beijing, China

7. Harbin Medical University Cancer Hospital, Harbin, China

8. Hematology, University Hospital “Ospedale di Circolo e Fondazione Macchi”—ASST Sette Laghi, University of Insubria, Varese, Italy

9. Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France

10. Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

11. Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

12. The Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, United Kingdom

13. Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain

14. Hospital Universitario Puerta de Hierro—Majadahonda, Madrid, Spain

15. Vseobecna fakultní nemocnice v Praze, Nové Město, Czech Republic

16. Calvary Mater Newcastle, Waratah, NSW, Australia

17. Henri-Becquerel Center, Rouen, France

18. Comprehensive Cancer Centers of Nevada, Las Vegas, NV

19. N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

20. Jewish General Hospital, McGill, University, Montreal, Canada

21. St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom

22. BeiGene Switzerland GmbH, Basel, Switzerland

23. BeiGene USA, Inc, San Mateo, CA

24. BeiGene (Shanghai) Co, Ltd, Shanghai, China

25. Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

Abstract

Deep and durable responses with zanubrutinib plus obinutuzumab in patients with R/R FL.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3